Gilead's HIV portfolio remains dominant but faces Medicare Part D pricing pressure, limiting future growth potential. New ...

Across the recent three months, 14 analysts have shared their insights on Gilead Sciences GILD, expressing a variety of opinions spanning from bullish to bearish. The following table encapsulates ...

Bay Area drug giant Gilead is plotting the trial of a groundbreaking, once-a-year HIV prevention drug lenacapavir.

Hi, everyone. My name is Daina Graybosch. I'm a Senior Analyst here at Leerink Partners, covering largely immuno-oncology and also Gilead, which is broader than immuno-oncology. But today ...

After Gilead Sciences' lenacapavir made waves with stellar clinical results as a twice-yearly HIV prevention candidate, the drug has shown promise being dosed even further apart at only once a year.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

Morgan Stanley analyst Terence Flynn raised the firm’s price target on Gilead (GILD) to $130 from $123 and keeps an Overweight rating on the ...

We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...

Your FREE insider update on the biggest news stories and investing trends, delivered midday TheChart of the Day belongs to ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Last year, Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against infection with just a single injection every six months.